Studies Flashcards
What are the major RT dose escalation trials?
MRC RT01
Dutch CKVO96-10
PROG 9509
MD Anderson (Kuban)
What are the trials that examine short term ADT + RT vs. RT alone?
TROG 96.01 D'Amico RTOG 9408 Quebec L-101 RTOG 8610
What are the trials that examine long term ADT + RT vs. RT alone?
RTOG 8531
EORTC 22863
Quebec L-101
Casodex EPC
Arms for TROG 9601?
RCT comparing 3 VS 6 MO ADT VS RT ALONE
What are the trials that examine neoadjuvant ADT vs. adjuvant?
RTOG 9413
Arms for RTOG 8531?
RT Alone vs. RT + ADT until progression
Arms for CASODEX EPC trial?
RT Alone vs. RT + antiandrogen until progression
What trials evaluated duration of ADT with RT?
RTOG 9202 Quebec L-200 Canadian trial TROG 96.01 EORTC 22961 ICORG 97.01 PCS IV
SPCG-7 CATEGORY
RCT LONG TERM ADT WITH FLUTAMIDE +/- EBRT
Studies evaluating pelvic nodal RT vs. no pelvic nodal RT?
RTOG 7706
GETUG 01
RTOG 9413
Current RCTs examining adjuvant and salvage RT?
RADICALs
GETUG-1
RAVES
RCT examining adjuvant RT +/- casodex?
RTOG 9601
EUROPEAN STUDY RCT EXAMINING ADJUVANT RT VS. OBS
EORTC 22911
GERMAN RECT EXAMINING ADJUVANT RT VS. OBS?
GERMAN ARO 96-02
RCT examining 3 vs 10 mo ADT +RT vs. RT alone?
Quebec L-101
University of Calgary RCT major results?
Cryotherapy vs. RT
7 year bF 27% vs. 32%, NS
5 year OS 90% vs. 88%, NS
University of Calgary RCT toxicity results?
Cryotherapy vs. RT
G3-4 GU 9% vs. 6%, NS
G3-4 GI 3% vs. 7%, NS
Sexual potency 4% vs. 26%, SS
University of Calgary inclusion criteria?
cT2-3 N0
PSA < 20
Prostate volume < 60 cc
***PLND if GS 8+
EORTC 22911 inclusion criteria
75 yo or less
pT3a or b or positive margin
Undectable PSA was not required
In EORTC 22911 what percentage of patients had a PSA > 0.2?
29.9%
EORTC 22911 arms?
Adjuvant radiation vs. observation
EORTC 22911 10 year locoregional relapse rate?
OBS vs. ADJ RT
16% vs. 7.3%, SS
EORTC 22911 major 10 year findings?
OBS vs. ADJ RT
bPFS 41% vs. 61%, SS
OS 80% vs. 76%, NS
EORTC 22911 RT details
PORT 60 Gy at 2 Gy/fx
Cone down at 50 Gy was done
No pelvic nodal RT
EORTC 22911 PEP
Biochemical failure defined as PSA > 0.2 measured on two separate occurrences
EORTC 22911 10 year toxicity
OBS vs. ADJ RT
G3 GU 2.5% vs. 5.3%, SS
G2-3 GI 2.5% vs. 1.9%, NS
ARO 9602 inclusion criteria
After RP for PC:
pT3-4 with +/- margins
Undetectable PSA after RP
75 years or less
RTOG 9202 inclusion criteria?
- T2c-T4
2. PSA < 150
RTOG 9202 arms?
- RT to 65-70 Gy + CADT for 4 months for flutimide and goserelin
- RT + CADT for 4 months and for an additional 2 years with goserelin alone
RTOG 9202 subgroup results for patients with GS 8-10 disease?
LT ADT improved with SS
- DFS (9% vs. 21%), SS
- DSS (66% vs. 80%), SS
- Local progression (27% vs. 17%), SS
- DM 40% vs. 25%, SS
- Biochemical failure 73% vs. 55%, SS
- OS 31% vs, 45%, SS
According to Brenner et al using data from SEER what is the risk of prostate radiation causing secondary cancers?
1/70 at 10 years, 1.4%
What was the purpose of Lawton’s 2005 RJ publication focusing on node positive patients from RTOG 8531?
RT vs. RT + immediate ADT and its impact on OS, bPFS, DM and local control
In Lawton’s 2005 RJ publication focusing on node positive patients from RTOG 8531, in patients treated with RT alone vs. RT + ADT what was 10 year OS? biochemical control? FFDM?
RT + ADT vs. RT Alone
bPFS: 35% vs. 5%, SS
FFDM: 67% vs. 52%, SS
OS: 47% vs. 31%, NS
In Lee et al 1994, Urology publication following 71 patients with pathologically positive nodes treated with RT alone, what was the 10 year OS, LC, and DM?
10 year LC: 45% DM: 82% RFS: 10% CSS: 25% OS: 20%
Which study compared early vs. delayed ADT alone for clinically node positive patients?
EORTC 30846
What was the median OS for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?
7.6 years
What was the 10 year PCSM for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?
57% at 10 years
What trials examined the question of long term ADT + RT. vs RT alone?
Casodex
EORTC 22961
RTOG 8531
EORTC 22863
